aav2-hchm
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02341807)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Prostanoid EP1 receptorSupplementation
PTGER1 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- aav2-hchm
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02341807 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2015 | Harvard University, Spark Therapeutics, University of Pennsylvania |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Spark Therapeutics | For profit | 1 | 1 | 1 | 2015 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1